XML 28 R12.htm IDEA: XBRL DOCUMENT
v3.20.4

Debt | 3 Months Ended
--- | ---
Jan. 31, 2021
Debt Disclosure [Abstract] |
Debt | Debt
(In millions) | January 31, 2021 |  | October 31, 2020
Overdraft and other credit facilities | $ | 50.8 |  |  | $ | 59.4 |
Term loan | 350.0 |  |  | 350.0 |
Less: unamortized debt issuance cost | (0.1) |  |  | (0.1) |
Short-term debt | $ | 400.7 |  |  | $ | 409.3 |
Revolving credit | 564.0 |  |  | 534.0 |
Term loans | 850.0 |  |  | 850.0 |
Other | 0.2 |  |  | 0.2 |
Less: unamortized debt issuance cost | (0.3) |  |  | (0.3) |
Long-term debt | 1,413.9 |  |  | 1,383.9 |
Total debt | $ | 1,814.6 |  |  | $ | 1,793.2 |
Term Loan Agreement on October 16, 2020 On October 16, 2020, the Company entered into a 364-day, $350.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent which matures on October 15, 2021. The funds were used to partially repay outstanding borrowings under the 2020 Revolving Credit Facility (as defined below). At January 31, 2021, the Company had $350.0 million outstanding under this agreement. Amounts outstanding under this agreement will bear interest, at the Company’s option, at either the base rate, or the adjusted LIBO rate, plus, in each case, an applicable rate of 0.00% in respect of base rate loans and 0.80% in respect of adjusted LIBO rate loans. The interest rate w as 0.94% at January 31, 2021. This agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio consistent with the 2020 Credit Agreement discussed below. Revolving Credit and Term Loan Agreement on April 1, 2020 On April 1, 2020, the Company entered into a Revolving Credit and Term Loan Agreement (the 2020 Credit Agreement), among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft. the lenders from time to time party thereto, and KeyBank National Association, as administrative agent. The 2020 Credit Agreement provides for (a) a multicurrency revolving credit facility (the 2020 Revolving Credit Facility) in an aggregate principal amount of $1.29 billion and (b) a term loan facility (the 2020 Term Loan Facility) in an aggregate principal amount of $850.0 million, each of which, unless terminated earlier, mature on April 1, 2025. In addition, the Company has the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $1.605 billion, subject to the discretionary participation of the lenders. Amounts outstanding under the 2020 Credit Agreement will bear interest, at the Company’s option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate, plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans, and between 0.75% and 1.50% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2020 Credit Agreement. During the term of the 2020 Revolving Credit Facility, the Borrowers may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reduction of the revolving commitment. The Company pays an annual commitment fee that ranges from 0.10% to 0.20% of the unused portion of the 2020 Revolving Credit Facility based upon the Company’s Total Leverage Ratio, as defined in the 2020 Credit Agreement. In addition to the annual commitment fee, the Company is also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2020 Credit Agreement. On April 1, 2020, the Company borrowed $850.0 million under the 2020 Term Loan Facility and $445.0 million under the 2020 Revolving Credit Facility and used the proceeds to repay the outstanding amounts under the previous credit agreement and an outstanding term loan, and for general corporate purposes. On October 30, 2020, the Company entered into Amendment No. 1 to the 2020 Credit Agreement (the First Amendment to the 2020 Credit Agreement). The First Amendment to the 2020 Credit Agreement modifies the 2020 Credit Agreement by, among other things, adding CooperVision International Limited as a revolving borrower and releasing certain borrowers in the 2020 Credit Agreement. At January 31, 2021, the Company had $850.0 million outstanding under the 2020 Term Loan Facility, $564.0 million outstanding under the 2020 Revolving Credit Facility and $724.6 million available under the 2020 Revolving Credit Facility, net of $1.4 million outstandi ng letters of credit. The interest rate on the 2020 Term Loan Facility w as 1.14% a t January 31, 2021. During the three months ended January 31, 2021, the Company expensed less than $0.1 million re lated to the debt issuance costs of the 2020 Term Loan Facility. The 2020 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2020 Credit Agreement: •Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times. •Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00. At January 31, 2021, the Company was in compliance with the Interest Cov erage Ratio at 25.53 to 1.00 and the Total Leverage Ratio at 2.10 to 1.00 for the 2020 Credit Agreement. The Company, after considering the potenti al impacts of the COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of these financial statements. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2020 for more details. The following is a summary of the maximum commitments and the net amounts available to us under credit facilities discussed above as of January 31, 2021:
(In millions) |  | Facility Limit |  | Outstanding Borrowings |  | Outstanding Letters of Credit |  | Total Amount Available |  | Maturity Date
2020 Revolving Credit Facility |  | $ | 1,290.0 |  |  | $ | 564.0 |  |  | $ | 1.4 |  |  | $ | 724.6 |  |  | April 1, 2025
2020 Term Loan Facility |  | 850.0 |  |  | 850.0 |  |  | n/a |  | — |  |  | April 1, 2025
2020 Term Loan |  | 350.0 |  |  | 350.0 |  |  | n/a |  | — |  |  | October 15, 2021
Total |  | $ | 2,490.0 |  |  | $ | 1,764.0 |  |  | $ | 1.4 |  |  | $ | 724.6 |  |  |

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details
Name: | us-gaap_DebtDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration